Can Mylotarg be used for CD33-positive AML?

Does Mylotarg treat CD33-positive AML?

Mylotarg (gemtuzumab ozogamicin) is used to treat acute myeloid leukemia (AML) that expresses CD33. CD33 is a surface antigen on many AML cells, and Mylotarg is an antibody-drug conjugate designed to target CD33-positive leukemia cells.

When is Mylotarg used in AML patients?

In practice, Mylotarg is typically considered for AML patients whose leukemia tests positive for CD33, including cases where clinicians want an AML treatment option that targets that antigen. The decision depends on the patient’s disease characteristics and treatment history, not only CD33 status.

What if the AML is CD33-negative?

If the leukemia does not express CD33, Mylotarg is generally not expected to work as effectively because its mechanism depends on targeting CD33. In that setting, clinicians usually choose an alternative AML therapy based on other biomarkers and overall risk.

How is CD33 positivity determined?

CD33 positivity is determined by standard diagnostic testing on the patient’s leukemia cells (commonly flow cytometry or related immunophenotyping methods). Treatment eligibility hinges on whether CD33 is detected at clinically meaningful levels.

Sources

• [1] DrugPatentWatch.com: https://www.drugpatentwatch.com/